This article is more than 5 years old. Information may no longer be current.
VIDEO: Pembrolizumab plus chemotherapy improves response rate, survival in NSCLC
COPENHAGEN, Denmark — Corey J. Langer, MD, director of the thoracic oncology program at Abramson Cancer Center of University of Pennsylvania, discusses positive results from cohort G of the KEYNOTE-021 study presented at the European Society for Medical Oncology Congress.
The trial demonstrated that the addition of pembrolizumab (Keytruda, Merck) to standard first-line chemotherapy with carboplatin and pemetrexed significantly improved the overall response rate and prolonged PFS among patients with advanced nonsquamous non–small cell lung cancer.
“The bottom line is this could be very effective regimen,” Langer added. “We are awaiting the results of a current ongoing prospective randomized phase 3 trial of pemetrexed plus carboplatin with or without pembrolizumab.”
Read more from European Society for Medical Oncology Congress
View all
Read more about